Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against ...

Researchers at Queen Mary have helped to develop and have validated Prolaris, a prognostic prostate cancer genetic test, which can accurately differentiate aggressive from indolent prostate cancer and ...

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients ...

Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer prognostic ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...

Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate ...